Preventing Type 2 Diabetes in At-Risk Cardiorenal Populations
Abstract
The convergence of cardiovascular disease, chronic kidney disease, and type 2 diabetes, collectively known as cardiovascular-kidney-metabolic syndrome, affects the majority of US adults. That construct spans a broader population than kidney disease alone, and this review is concerned with a narrower one: patients with chronic kidney disease who are prediabetic or otherwise at risk for incident type 2 diabetes. In these patients, prediabetes represents both a warning and an opportunity. Dysglycemia is common, its progression is detectable early, and preventing it is expected to benefit both the heart and the kidney, a benefit inferred from the mechanisms the two organs share rather than demonstrated directly in outcome trials in this population. Prediabetes is not uniform, and rates of progression and regression vary. Prevention here is not a metabolic problem applied to sicker patients. It is a cardiorenal strategy, because dysglycemia contributes to several of the mechanisms coupling the heart and kidney. This review examines the evidence for diabetes prevention in patients with chronic kidney disease, the identification of patients at highest risk, and the operational structure required to translate evidence into practice. Lifestyle modification remains the foundation and is supported by decades of durable evidence, adapted to the dietary and functional constraints of kidney disease, though real-world adherence falls short of what trial conditions achieved. Metformin is a…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.